Table 4.
Multivariate Analysis for Visual Acuity and its Change from Baseline at 1 Year
| VA score (letters) at 1 Year*
|
VA score change (letters) from baseline at 1 Year †
|
||||
|---|---|---|---|---|---|
| Baseline Characteristics | N | Adjusted Mean (SE) | P-value | Adjusted Mean (SE) | P-value |
| Age (years) | |||||
| 50–69 | 131 | 72.1 (1.3) | 0.0006 | 10.8 (1.3) | 0.003 |
| 70–79 | 387 | 68.8 (0.7) | 8.2 (0.8) | ||
| 80–89 | 512 | 66.4 (0.6) | 5.8 (0.6) | ||
| ≥90 | 75 | 67.2 (1.7) | 6.2 (1.7) | ||
| Baseline VA in study eye | |||||
| 68–82 letters, 20/25 - 20/40 | 397 | 76.4 (0.8) | <0.0001 | 3.3 (0.7) | <0.0001 |
| 53–67 letters, 20/50 - 20/80 | 414 | 69.1 (0.7) | 8.4 (0.7) | ||
| 38–52 letters, 20/100 - 20/160 | 223 | 59.0 (1.0) | 11.9 (1.0) | ||
| 23–37 letters, 20/200 - 20/320 | 71 | 41.7 (1.8) | 7.9 (1.7) | ||
| Baseline area of CNV (mm2) | |||||
| ≤2.54 | 443 | 69.9 (0.7) | 0.001 | 8.7 (0.7) | 0.02 |
| >2.54 to ≤5.08 | 219 | 68.0 (1.0) | 7.5 (1.0) | ||
| >5.08 to ≤10.2 | 207 | 67.0 (1.0) | 6.7 (1.0) | ||
| >10.2 | 103 | 64.5 (1.4) | 4.2 (1.4) | ||
| Can’t measure | 133 | 64.9 (1.4) | 4.8 (1.4) | ||
| Lesion type | |||||
| Predominantly or Minimally classic | 431 | 65.8 (0.7) | 0.0003 | -- | |
| Occult only | 650 | 69.3 (0.6) | -- | ||
| RAP lesion | |||||
| No | 966 | -- | 6.9 (0.5) | 0.03 | |
| Yes | 118 | -- | 10.1 (1.3) | ||
| Geographic atrophy | |||||
| None/questionable | 1027 | 68.2 (0.5) | 0.02 | -- | |
| Present | 76 | 63.9 (1.7) | -- | ||
| Total foveal thickness (μ) | |||||
| 1st quartile (≤325) | 277 | 68.0 (0.9) | 0.01 | -- | |
| 2nd quartile (>325 to ≤425) | 285 | 69.7 (0.9) | -- | ||
| 3rd quartile (>425 to ≤550) | 253 | 68.7 (0.9) | -- | ||
| 4th quartile (>550) | 285 | 65.5 (0.9) | -- | ||
| RPE elevation | |||||
| No | 145 | 71.2 (1.2) | 0.005 | 10.5 (1.2) | 0.004 |
| Yes | 944 | 67.5 (0.5) | 6.8 (0.5) | ||
| Treatment Group | |||||
| Ranibizumab Monthly | 284 | 69.4 (0.9) | 0.045 | 8.6 (0.9) | 0.07 |
| Bevacizumab Monthly | 265 | 68.6 (0.9) | 7.9 (0.9) | ||
| Ranibizumab as needed | 285 | 67.5 (0.9) | 6.9 (0.9) | ||
| Bevacizumab as needed | 271 | 66.2 (0.9) | 5.5 (0.9) | ||
SE = Standard Error; VA= Visual Acuity; CNV= choroidal neovascularization; RAP=Retinal Angiomatous Proliferans; RPE=Retinal Pigment Epithelium.
*
A total of 1061 participants were included in the final multivariate model, and 44 patients were excluded due to missing value in one or more predictors.
†
A total of 1068 participants were included in the final multivariate model, and 37 patients were excluded due to missing value in one or more predictors.
--: predictor was not included in the final multivariate model, because it was not statistically significant.